Bristol-Myers Squibb's BMS-986036 meets primary endpoint in Phase II trial to treat NASH

Bristol-Myers Squibb (BMS) has reported positive results from a Phase II clinical trial of BMS-986036 to treat non-alcoholic steatohepatitis (NASH) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news